Toggle Offcanvas
...
 
Axitinib Tenders

Axitinib Tenders

View Axitinib tenders, RFPs and contracts. Bid on readily available Axitinib tenders with the best and most comprehensive tendering platform, since 2002.
Axitinib is a tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma. It works by blocking vascular endothelial growth factor receptors VEGFRs , inhibiting tumor angiogenesis. Axitinib has shown significant benefits in prolonging survival in patients with kidney cancer.

Bidding for Axitinib tenders is extremely lucrative for companies of all sizes. Tendering authorities and private companies release thousands of contracts worth millions for procurement of Axitinib.

Global Tenders stands out as the largest platform dedicated to pharmaceutical tenders and government contracts. Boasting over 20 years of experience in the tender business, GlobalTenders offers the most extensive and reliable Tenders/RFPs/Contracts Database available. The platform aggregates contracts from both public and private sources, connecting with a vast network of over half a million buyers. Employing advanced artificial intelligence, our meticulous process involves gathering information from over a hundred thousand sources. The data is then intelligently categorized into thousands of subcategories for easy filtering and presenting it in a user-friendly format for quick comprehension.

In addition to tender information, we offer in-depth Axitinib market analysis, bid consultancy services, and insights into top bidders and winners.

Sign up now to get instant access to unlimited Axitinib tenders, advanced search filters, market analysis, industry trends, tender training and 24/7 customer support.

13 Live Notices for Axitinib Tenders

Showing 1 to 13

Object: Electronic Auction - Acquisition Of Medicines To Meet Judicial Determination
country Brazil
posting date11 Jul 2025
deadline25 Jul 2025
Medicinal Products Containing Axitinib And Elnatamab
country Czech Republic
posting date26 Jun 2025
deadline25 Jul 2025
Completion Of Non-Exclusive Discount Agreements According To § 130 A (8) Sgb V From 01.07.2025
country Germany
posting date27 May 2025
deadline10 Nov 2026
Medicines With The Active Ingredient Axitinib (Atc: L01Ek01)
country Germany
posting date19 May 2025
deadline30 Apr 2027
Open House Pharmaceutical Discounts On The Active Ingredient Axitinib, Atc L01Ek01
country Germany
posting date19 May 2025
deadline30 Apr 2027
Medicines With The Active Ingredient Axitinib (Atc: L01Ek01)
country Germany
posting date19 May 2025
deadline30 Apr 2027
Open House Pharmaceutical Discounts On The Active Ingredient Axitinib, Atc L01Ek01
country Germany
posting date19 May 2025
deadline30 Apr 2027
Open House Pharmaceutical Discounts On The Active Ingredient Axitinib, Atc L01Ek01
country Germany
posting date19 May 2025
deadline30 Apr 2027
Open House Medicinal Department Axitinib, Atc L01Ek01
country Germany
posting date16 May 2025
deadline05 May 2027
Open House Medicinal Department Axitinib, Atc L01Ek01
country Germany
posting date16 May 2025
deadline05 May 2027
Completion Of A Non-Exclusive Discount Contract According To Section 130A (8) Sgb V On Pharmaceuticals With The Active Ingredient Axitinib (Atc Code: L01Ek01).
country Germany
posting date14 May 2025
deadline27 Apr 2027
Completion Of A Non-Exclusive Discount Contract According To Section 130A (8) Sgb V On Pharmaceuticals With The Active Ingredient Axitinib (Atc Code: L01Ek01).
country Germany
posting date13 May 2025
deadline27 Apr 2027
Pharmaceutical Discount Contracts From 01.07.2025 On Various Active Ingredients As Part Of An Open House Procedure
country Germany
posting date13 May 2025
deadline03 May 2027

Share Share this page